Perspective Therapeutics ...

2.13
-0.07 (-3.18%)
At close: Mar 31, 2025, 11:43 AM

Company Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.

It sells its products to facilities or physician practices that utilize various surgical facilities.

The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022.

Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

Perspective Therapeutics Inc.
Perspective Therapeutics Inc. logo
Country United States
IPO Date Nov 10, 2005
Industry Medical - Devices
Sector Healthcare
Employees 138
CEO Johan M. Spoor

Contact Details

Address:
350 Hills Street
Richland, Washington
United States
Website https://www.perspectivetherapeutics.com

Stock Details

Ticker Symbol CATX
Exchange AMEX
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000728387
CUSIP Number 46489V302
ISIN Number US46489V3024
Employer ID 41-1458152
SIC Code 3841

Key Executives

Name Position
Johan M. Spoor Chief Executive Officer & Director
Juan Graham Chief Financial Officer
Amos Hedt BA, PGradDip Chief Business Strategy Officer
Andrew Bright Executive Vice President of Brachytherapy
Annie J. Cheng Vice President of Investor Relations
David Hauser Ph.D. Senior Vice President of Clinical Operations
Dr. Markus Puhlmann M.B.A., M.D. Chief Medical Officer
Dr. Michael K. Schultz Ph.D. Chief Science Officer
Jonathan R. Hunt Chief Accounting Officer
Shane Cobb Executive Vice President of Operations

Latest SEC Filings

Date Type Title
Mar 28, 2025 10-K/A [Amend] Annual Report
Mar 26, 2025 S-8 Filing
Mar 26, 2025 POS AM Filing
Mar 26, 2025 10-K Annual Report
Mar 26, 2025 8-K Current Report
Mar 26, 2025 POSASR Filing
Mar 17, 2025 8-K Current Report
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing
Mar 05, 2025 4 Filing